Logo image of HLVX

HILLEVAX INC (HLVX) Stock Fundamental Analysis

NASDAQ:HLVX - Nasdaq - US43157M1027 - Common Stock - Currency: USD

1.85  0 (0%)

After market: 1.85 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to HLVX. HLVX was compared to 567 industry peers in the Biotechnology industry. HLVX has a great financial health rating, but its profitability evaluates not so good. HLVX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

HLVX had negative earnings in the past year.
In the past year HLVX has reported a negative cash flow from operations.
HLVX had negative earnings in each of the past 5 years.
HLVX had a negative operating cash flow in each of the past 5 years.
HLVX Yearly Net Income VS EBIT VS OCF VS FCFHLVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -76.43%, HLVX is doing worse than 67.90% of the companies in the same industry.
The Return On Equity of HLVX (-95.33%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -76.43%
ROE -95.33%
ROIC N/A
ROA(3y)-54.23%
ROA(5y)-132.64%
ROE(3y)-67.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HLVX Yearly ROA, ROE, ROICHLVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for HLVX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HLVX Yearly Profit, Operating, Gross MarginsHLVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, HLVX has more shares outstanding
HLVX has more shares outstanding than it did 5 years ago.
HLVX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
HLVX Yearly Shares OutstandingHLVX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
HLVX Yearly Total Debt VS Total AssetsHLVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

HLVX has an Altman-Z score of -3.26. This is a bad value and indicates that HLVX is not financially healthy and even has some risk of bankruptcy.
HLVX has a Altman-Z score of -3.26. This is comparable to the rest of the industry: HLVX outperforms 48.50% of its industry peers.
There is no outstanding debt for HLVX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.26
ROIC/WACCN/A
WACCN/A
HLVX Yearly LT Debt VS Equity VS FCFHLVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 10.84 indicates that HLVX has no problem at all paying its short term obligations.
HLVX's Current ratio of 10.84 is amongst the best of the industry. HLVX outperforms 82.36% of its industry peers.
A Quick Ratio of 10.84 indicates that HLVX has no problem at all paying its short term obligations.
HLVX has a Quick ratio of 10.84. This is amongst the best in the industry. HLVX outperforms 82.54% of its industry peers.
Industry RankSector Rank
Current Ratio 10.84
Quick Ratio 10.84
HLVX Yearly Current Assets VS Current LiabilitesHLVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

HLVX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.32%.
EPS 1Y (TTM)1.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.82%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, HLVX will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.16% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y53.76%
EPS Next 2Y24.41%
EPS Next 3Y15.04%
EPS Next 5Y10.16%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HLVX Yearly Revenue VS EstimatesHLVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 50M 100M 150M 200M
HLVX Yearly EPS VS EstimatesHLVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HLVX. In the last year negative earnings were reported.
Also next year HLVX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HLVX Price Earnings VS Forward Price EarningsHLVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HLVX Per share dataHLVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as HLVX's earnings are expected to grow with 15.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.41%
EPS Next 3Y15.04%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HLVX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HILLEVAX INC

NASDAQ:HLVX (4/25/2025, 8:13:15 PM)

After market: 1.85 0 (0%)

1.85

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-28 2025-03-28/amc
Earnings (Next)N/A N/A
Inst Owners54.36%
Inst Owner Change-35.26%
Ins Owners2.24%
Ins Owner Change-0.15%
Market Cap92.76M
Analysts47.5
Price Target2.04 (10.27%)
Short Float %5.27%
Short Ratio7.76
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-63.02%
Min EPS beat(2)-104.08%
Max EPS beat(2)-21.96%
EPS beat(4)0
Avg EPS beat(4)-35.91%
Min EPS beat(4)-104.08%
Max EPS beat(4)-4.06%
EPS beat(8)4
Avg EPS beat(8)-10.52%
EPS beat(12)6
Avg EPS beat(12)-24.58%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-14.28%
PT rev (3m)-33.33%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)25.82%
EPS NY rev (3m)28.98%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.6
P/tB 0.6
EV/EBITDA N/A
EPS(TTM)-3
EYN/A
EPS(NY)-1.39
Fwd EYN/A
FCF(TTM)-2.18
FCFYN/A
OCF(TTM)-2.17
OCFYN/A
SpS0
BVpS3.08
TBVpS3.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -76.43%
ROE -95.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.23%
ROA(5y)-132.64%
ROE(3y)-67.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.32%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.84
Quick Ratio 10.84
Altman-Z -3.26
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.82%
EPS Next Y53.76%
EPS Next 2Y24.41%
EPS Next 3Y15.04%
EPS Next 5Y10.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.28%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-12.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.36%
OCF growth 3YN/A
OCF growth 5YN/A